SeQure Dx, Inc.

SeQure Dx, Inc. is a Massachusetts-based healthcare company specializing in advanced diagnostic solutions aimed at improving disease detection and management for healthcare providers. Founded in 2020 and headquartered in Waltham, Massachusetts, SeQure Dx, Inc. provides innovative diagnostic tools and platforms that enhance patient data analysis.

The company was acquired by MaxCyte, Inc. in January 2025 for USD 4. 5 mn. The founder, Keith Joung, has a history in developing healthcare technologies.

SeQure Dx has raised a total of USD 17. 5 mn across multiple funding rounds, with the most recent round being an Add-on Trade Sale with MaxCyte, Inc. as the investor. SeQure Dx specializes in providing advanced diagnostic solutions tailored for the healthcare sector, focusing primarily on enhancing disease detection and management.

Their core product offerings include a suite of diagnostic tools and platforms designed to analyze patient data, facilitating more accurate and timely diagnoses. These solutions address critical use cases in early disease detection, chronic illness monitoring, and streamline patient care protocols. SeQure Dx serves a diverse clientele, including hospitals, clinics, and research institutions across North America, Europe, and parts of Asia, responding to the demand for innovative healthcare technologies. SeQure Dx's revenue model is primarily structured around B2B transactions, focusing on partnerships with healthcare providers and institutions.

The company engages in subscription-based agreements for its diagnostic platforms, providing ongoing access to essential tools and updates for effective patient management. Additionally, SeQure Dx enters into licensing agreements for its proprietary technologies, allowing clients to integrate these solutions into their existing infrastructures. Pricing plans for flagship products are tailored to meet client needs, ensuring alignment with operational scale and scope. In January 2025, SeQure Dx, Inc.

was acquired by MaxCyte, Inc. , which aims to leverage the company's scientific support and complementary offerings to enhance the safety and precision of cell therapies. The acquisition may include contingent consideration of up to USD 2. 5 mn based on revenue targets.

Following this acquisition, the company plans to expand its product line and enter new markets, specifically targeting growth in Europe and Asia by 2026. The recent funding will be utilized to support these initiatives and further development of diagnostic solutions.